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Introduction: Craniopharyngioma of childhood are commonly cystic in nature. An intra-
cystic catheter insertion and subsequent instillation of substances inducing cyst shrinkage
seems a beneﬁcial strategy avoiding additional morbidity in a highly vulnerable brain loca-
tion. Methods: A systematic review of the medical literature was performed to identify
potentially relevant, all languages articles using Ovid MEDLINE and EMBASE from incep-
tion to July 2011 and Cochrane Central Register of ControlledTrials to third quarter 2011. All
references were examined for relevancy. Results: Of 142 unique references, 71 referred
to substances used for intracystic craniopharyngioma treatment. General aspects of intra-
cystic catheter insertion as well as response rates, risks, and outcomes of children treated
with intracystic radioisotopes, bleomycin, and interferon (IFN) are critically reviewed and
an outline for potential future endeavors provided. Conclusion: IFN seems currently the
intracystic substance with the best beneﬁt risk ratio.The authors advocate for consensus
on prospective data collection and standardized intracystic treatment strategies to allow
reliable comparisons and herewith optimize treatment and outcome.
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INTRODUCTION
Craniopharyngioma of childhood are commonly cystic in nature.
These tumors are histologically benign, corresponding to WHO
grade I and are usually not life threatening. Benign lesions in
the brain are considered cured when amenable to surgical resec-
tion, however even gross total resection of craniopharyngioma is
not always curative and may be associated with signiﬁcant addi-
tional morbidities (Müller,2010). Craniopharyngioma diagnosed
in childhood will affect the developing child, the maturing brain
and body via effects on the visual, endocrinological, metabolic,
and neurocognitive functions in a more signiﬁcant way as com-
paredtoadults.ThereforetheHippocrates’basicprinciple“tohelp
or at least to do no harm” is the ultimate challenge when deter-
miningthebestmeansfortreatingchildhoodcraniopharyngioma
and minimizing morbidity is a major goal.
Hence the prospect of a minimally invasive intervention –
such as an endoscopic insertion of a catheter with a subcutanous
Ommaya reservoir – and subsequent instillation of substances
inducing shrinkage of the craniopharyngioma cyst(s), seems a
promising strategy. The following article reviews the experiences
and outcomes of children treated with intracystic therapies pro-
viding a critical summary and an outline for potential future
endeavors.
METHODS
A systematic review of the medical literature was performed to
identify potentially relevant, all languages articles using Ovid
MEDLINE and EMBASE from inception to July 2011 and
Cochrane Central Register of Controlled Trials to third quarter
2011. The search strategy comprised a text search with medical
subject headings (MeSH) and free text terms used in combination
including craniopharyngioma, intracystic treatment, cyst∗, anti-
neoplastic, and antibiotic. The total retrieval was 211 references
from the 3 databases. All references were saved in an EndNote
library used to identify the 69 duplicates for a total of 142 unique
references. All references were examined for relevancy.
RESULTS
NEUROSURGICAL ASPECTS OF INTRACYSTIC CATHETER INSERTION
Fenestration as a “minimal” surgical intervention in the treat-
ment of cystic craniopharyngioma was employed by Cushing in
1930. He and others recognized early on that the beneﬁt from
this intervention was of short duration with recurrence of symp-
toms within a short period of time (Kramer et al.,1961). This still
holdstrueinarecentstudywhichconﬁrmedhighrecurrencerates
whensurgerywaslimitedtocystfenestrationevenwithcombined
adjuvant Gamma knife surgery (Park et al.,2011).
Aninsertionof acatheterintoacysticcraniopharyngiomamay
prevailoverthetransientsuccessof acystfenestrationbyallowing
repetitivedrainageof thetumorcystandtheopportunityof instil-
lationofintracysticsubstances.Differentneurosurgicaltechniques
are employed for the placement of catheters.
Surgical strategies for intracystic catheter placement are
reported in a retrospective review of 50 cystic craniopharyngioma
patients treated at two French (Paris, Marseille) and three Brazil-
ian (Belo Horizonte, Goiânia, São Paulo) institutions between
1990 and 2000. The authors distinguish three different patient
groups according to the different surgical approaches. Although
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with limited certainty from the data provided, the study included
mainly pediatric patients. There is an age range (9months to
21years) given for the 25 female patients;a median age of 10years
is indicated for the male patients. Group one (n =26) had their
catheters placed either via frontal or pterional craniotomy under
direct vision. Group two (n =14) underwent stereotactic place-
ment and group three (n =11) had free hand placement through
a burr hole. All catheters were connected to either a Rickham
(n =23) or an Ommaya reservoir subcutaneously. One to two
weeks after the surgical intervention a permeability study (injec-
tion of contrast medium into the cyst via reservoir) using either
X-ray or CT was undertaken revealing contrast leakage or mis-
placement of the intracystic catheter in eight children (16.3%).
This study did not ﬁnd a difference in complications between
the three different surgical methods and reported that no other
catheter placement related complication occurred in this series
(Zanon et al., 2008).
Pettorinietal.(2009)advocatethatneuroendoscopicposition-
ing of the catheter is a safer option than open or stereotactic
approaches. In their case series of eight patients (ﬁve children
withameanage3.8years)withsymptomaticcysticcraniopharyn-
gioma the placement of the catheter via endoscopy with a Storz
rigid ventriculoscope was without complications except one tech-
nical failure (12.5%). The technical failure occurred in a child
with an extensively calciﬁed cyst wall that made positioning of
the catheter impossible. For planning reasons a pre-op CT seems
important as calciﬁcations could be missed on MRI scans which
arecommonlythepreferredimagingmodalityinchildreninorder
to minimize radiation exposure. Other advantages in using the
endoscopicapproacharethepossibilitytoperformaseptostomyat
thesametime,aninterventionthatestablishesconnectionbetween
lateral ventricles and subsequently facilitates successful shunting.
Stereotactic endoscopic technique as a safe and effective pro-
cedure for catheter insertion in cystic craniopharyngioma is sup-
ported by Joki et al. (2002). Hellwig et al. (1995) describe effective
management in more than 70 cystic intracerebral space occupy-
inglesionswithoutmajortissuetraumatization.Theyreportedan
operative morbidity of less than 3% and no operative mortality.
There are anatomic constraints that may limit the stereo-
tactic accessibility of a craniopharyngioma cyst which relate to
infra- or suprasellar location and the vulnerability of the adjacent
critical structures such as optic apparatus, pituitary gland, and
hypothalamus (Floyd et al.,2009).
Theexperienceoftheoperatingneurosurgeoninacertaintech-
nique will ultimately affect the outcome. Interestingly in a study
by Sanford (1994) the experience of the operating neurosurgeon
was proven statistically signiﬁcant with respect to the quality of
life of craniopharyngioma patients.
INSTILLATION OF SUBSTANCES
The majority of cystic craniopharyngioma arise from squamous
epithelium (Ingraham and Scott, 1946; Kramer et al., 1961; Louis
et al., 2007). Intracystic instilled substances should have the abil-
ity to destroy the secretive properties of the epithelial cell lin-
ing to induce cyst shrinkage and ideally subsequent adhesion
of the cyst wall. Substances should remain within the cyst and
should not cause any harm to the surrounding brain in case of
leakage.Substancesusedforcysticcraniopharyngiomashavebeen
radioisotopes, Bleomycin, and Interferon (IFN) (Table 1).
Intracystic instillation of β emitting radioisotopes including
aurum198, rhenium186, yttrium90, and phosphorus32 has been
reportedsuccessfulininducingcraniopharyngiomacystshrinkage
in multiple studies over more than four decades (Backlund, 1973,
1989; Musolino et al., 1985; Voges et al., 1997; Hasegawa et al.,
2004).
While phosphorus32 is the only β emitting radionucleotide
available for use in the USA, rhenium186, yttrium90, and
phosphorus32 are available and used in Europe (France/Hungary/
Germany)(Vogesetal.,1997;Julowetal.,2007;Derreyetal.,2008).
Physicalcharacteristicsof βemittingradioisotopesmaydetermine
preferences.Someauthorsfavorphosphorus32 withalowerenergy
(mean β energy of 0.69MeV), longer half life (14.3days), and
less tissue penetration (2–8mm; Pollock et al., 1995) while others
argue that yttrium90 (mean β energy of 0.93MeV, 2.7days half
life, tissue penetration 11mm) is superior due to its higher emit-
ting dose during a shorter time period (Blackburn et al., 1999).
Clinicalstudies,mostlyinstitutionalretrospectiveseries,areequiv-
ocal regarding the clinical superiority of a radioisotope. Voges
et al. (1997) observed no cyst response to intracystic rhenium186,
while intracavitary irradiation using yttrium90 or phosphorous32
was highly effective resulting in 79.5% response rates. In a more
recent study including 11 children within 42 eligible patients,
the instillation of colloidal rhenium186 resulted in 74% response
rate including 17 patients with complete cyst retraction and 12
patients with >50% reduction in cyst volume (Derrey et al.,
2008). Barriger et al. (2011) report an overall cyst control rate
of 67% with intracystic phosphorus32 in 19 patients between 3
and 54years of age.
Radioisotope doses require adjustment to cyst volume. The
optimal prescribed dose to the cyst wall is 200–300Gy (Hecht-
manetal.,2005;Sadeghietal.,2007)upto400Gywithsigniﬁcant
increasedrisksespeciallytotheopticapparatusoncedosessurpass
400Gy (Derrey et al., 2008; Floyd et al., 2009). There is evidence
thatcystvolumesexceeding100mlwillnotrespondwell(Albright
et al.,2005).
Instillation of phosphorus32 into a recurrent infrachiasmatic
cystic craniopharyngioma of a 36-old-female via an neuroen-
doscopic transnasal route was described recently (Floyd et al.,
2009) and is certainly an elegant minimal invasive intervention.
A therapeutic effect was achieved with one instillation only and
therefore the insertion of a permanent catheter with reservoir was
notrequired.Howeveracatheterimplantationisusuallyemployed
for radioisotopes injection and removal (Derrey et al.,2008).
Access to radioisotopes is only available in a limited number of
institutions requiring sophisticated equipment and a multidisci-
plinary team of experts and there is advocacy using this treatment
approach only for tumors that recur after both surgery and exter-
nal beam radiation therapy (Becker et al., 1999; Merchant et al.,
2006).
In1974theeffectofbleomycin forculturedcraniopharyngioma
cells and intracystic concentration of bleomycin was published by
Kubo et al. (1974). Based on their morphological observations
of destruction of cell arrangement, cytolysis, and karyopyknosis
theyconcludeditslocalcytotoxicpotencytocraniopharyngiomas.
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Table 1 | Intracystic treatment modalities in craniopharyngiomas – retrospective reviews including children.
Reference Patients
(kids)
Median/mean
age (range)
in years
CR PR Median/mean
f/up (range)
in years
Median/mean
PFS (range)
in years
Reported complications or toxicities
ISOTOPES
Pollock et al. (1995) 30 (10) 35 (3–70) 0.10 0.83 3.1 (0.6–9.7) NR Three new behavioral problems, visual decline,
three new onset DI
Voges et al. (1997) 62 (32) 17 (4–71) 0.45 0.35 11.9 (1.5–16.4) NR Three amaurosis, one visual ﬁeld cut, three
endocrine deﬁcits, one death 9months after
treatment
Hasegawa et al. (2004) 49 (15) 29 (3–74) 0.17 0.59 4.1 NR Visual or endocrine deterioration
Julow et al. (2007) 60 (13) 27 .7 (2.9–67 .5) 0.45 0.30 NR NR Three visual deterioration, six transient CN III
palsy, one death/meningoventriculitis 6weeks
after intervention, two hypothalamic/thalamic
vascular injury
Derrey et al. (2008) 42 (11) 38.7 (5–85) 0.44 0.44 3.6 (0.7–12.3) NR Two septic meningitis, two chemical
meningitis, one intracranial hypertension, two
centralhyperthermia;threevisualacuityorﬁeld
decline, one memory loss
Barriger et al. (2011) 19 (NR) 20 (3–54) 0.05 0.26 5.2 (0.7–11.3) 0.8 (0.1–4.5) Six increased pituitary deﬁciencies, one new
ﬁeld deﬁcit
BLEOMYCIN
Takahashi et al. (1985)* (7) 8.4 (2–13) NR NR NR (21–26) 12 (0.1–26)# Transient mild fever
Hader et al. (2000) (9) 8.4 (2.5–14) 0.14 0.71 3 (0.5–5) NR Two transient headaches and fever, one panhy-
popituitarism
Mottolese et al. (2001) 24 (20) 14.3 (0.25–64) 0.38 0.63 5 5 (2–10) One blindness (after toxic dose)+
Park et al. (2002) 10 (5) 30.2 (3–65) NR NR 2.8 (1–6.6) NR One visual disturbance, one cerebellar
infarction/death, one hypersomnia/memory
impairment,onetransientmentalchanges,one
bedridden
Mottolese et al. (2005) (24) NR (6–16) 0.50 0.25 6.7 (1–14) NR One blindness (after toxic dose)+; three new
onset of DI, 11 endocrine insufﬁciency, visual
deterioration
Takahashi et al. (2005) (11) NR (2–14) 0.27 0.64 NR (3–16) NR Onehypothalamic–pituitaryinsufﬁciency/death
during f/up
Hukin et al. (2007) (17) 6 (1–14) 0.29 0.35 5 (0.5–10.2) 0.7 (0.3–6.1)$ Decreased level of consciousness/
panhypopituitarism, one multiple CN
deﬁcits/hemiparesis
Hsu et al. (2009) (9) 7. 8 (3.3–11.8) NR NR 3.7 (0.8–6.6) 2.4 (0.2–6.6) NR
INTERFERON
Cavalheiro et al. (2005) (9) 10 (1.8–18) 0.78 0.22 1.8 (1–3.5) NR One arthralgia/chronic fatigue/depression
Ierardi et al. (2007) (21) 10 (1–19) 0.50 0.50 2.25 (0.5–4) NR NR
Cavalheiro et al. (2010) (60) 11 (1.6–18) NR 0.78 3.7 (0.3–7) NR Transient headache/fever/fatigue/arthritis; eight
new endocrinological dysfunction
*Including f/up data provided inTakahashi et al. (2005).
#Estimate from authors based on provided data.
+Likely same patient.
$Refers to 12 patients treated at the time of the initial diagnosis.
NR, not reported; PFS, progression free survival; CR, complete response; PR, partial response (≥50% shrinkage); f/up, follow-up; CN, cranial nerve.
Theyweretheﬁrsttoreportonintracysticbleomycintreatmentin
an 8-year-old boy with craniopharyngioma who had failed radia-
tion.Amixtureof bleomycin,dextransulfate,anddexamethasone
was injected into his cyst via ommaya reservoir. Treatment was
given twice during the ﬁrst week. No signiﬁcant side effects were
observedandsubsequentlyintracysticinjectionsweregiven5days
during the second week, followed by instillations every second
day on an outpatient basis. A total dose of 30mg bleomycin
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was administered resulting in partial cyst reduction as evaluated
with pneumocystography. The boy was reported well at 1month
follow-up.
Takahashi et al. (1985) published a case series on seven chil-
dren with craniopharyngioma treated with intracystic instillation
of Bleomycin.By labeling Bleomycin with cobalt-57 and subse-
quent measurements with a gamma-ray camera a 3h half life of
intracysticBleomycinwithadropto10%oftheinitialactivity24h
later was calculated. This surveillance determined the subsequent
treatmentregimenadministeringintracysticinstillationof1–5mg
bleomycineveryotherday.Theauthorsfurtherobservedthatwith
ongoing intracystic instillation of bleomycin the initial motor-oil
like ﬂuid content changed to nearly colorless ﬂuid and initial high
lactatedehydrogenase(LDH)levelsdropped.Hencetreatmentwas
given until cystic ﬂuid became almost colorless and LDH levels
decreased below 1000 units. The seven children received a mean
dose of 46mg of intracystic bleomycin ranging from 13 to 95mg.
Four children had sustained response without evidence of pro-
gression at 2, 4, and 7years follow-up. Three children died, two
of them due to recurrent disease 1.5 and 2years later respectively.
One child died 1.5months later without evidence of progression;
further details are lacking. Autopsies in two of the children did
not reveal any bleomycin associated changes in the adjacent brain
structures.
Since Takahashi’s publication in 1985 several pediatric case
reports (Cavalheiro et al., 1996; Savas et al., 1999; Alen et al.,
2002) and retrospective institutional case series conﬁrmed intra-
cystic bleomycin’s effectiveness in inducing craniopharyngioma
cyst shrinkage with sustained response rates in children (Taka-
hashi et al., 1985, 2005; Hader et al., 2000; Franzini et al., 2001;
Mottolese et al., 2001, 2005; Hernandez et al., 2002; Park et al.,
2002; Hukin et al., 2005, 2007; Kim et al., 2007; Hsu et al., 2009;
Yang et al., 2009). All studies refer to small sample sizes includ-
ing a maximum of 22 pediatric patients (Franzini et al., 2001)
with ﬁve studies reporting response to treatment in all patients
(Mottolese et al., 2001; Park et al., 2002; Hukin et al., 2005; Taka-
hashi et al., 2005; Kim et al., 2007). Complete response rates in
children vary from 29% as provided by the Canadian experience
(Hukin et al., 2007) to 67% (Mottolese et al., 2005)i nt h eL y o n
experience, where 12 of 18 children showed disappearance of the
cyst with maintained responses at a mean follow-up of 6years
8months.
Theschedulesof bleomycinadministrationanddosesvaryand
rangefromdailytoweeklyadministrationswithsingledosesrang-
ing from 1 to 15mg and total doses ranging from 14.5 to 180mg
per course (Takahashi et al., 1985; Jiang et al., 2002; Park et al.,
2002). No standardized regimen has been established. Of note
is that the former bleomycin mg dose was labeled a misnomer
and should be substituted by Unit (1mg equals 1U). Stefanou
underscored the considerable problems and dangers due to dif-
ferent bleomycin nomenclature in the US, Europe, and Australia
and advocated for standardization as a mean to minimize dosing
errors (Stefanou and Siderov, 2001).
Several studies investigated intracystic ﬂuid LDH to prognos-
ticate tumor response. While some studies observed decreased
LDH levels consistent with response and increased LDH levels
with recurrence (Takahashi et al., 1985; Park et al., 2002) others
did not conﬁrm LDH levels reﬂective of tumor response (Caval-
heiro et al.,1996; Mottolese et al.,2001; Jiang et al.,2002; Caceres,
2005).
Intracystic bleomycin is usually well tolerated and most com-
mon acute side effects include mild headaches (with or without
nausea/vomiting) and transient fever. However serious concerns
relate to the risk of leakage of the neurotoxic bleomycin into the
cyst surrounding parenchyma with associated morbidities and
even mortality. Despite veriﬁcation of appropriate positioning of
the catheter intracystic bleomycin is associated with a risk of sig-
niﬁcanttoxicitiesincludingtransientandpersistenthypothalamic
injury (Haisa et al., 1994; Park et al., 2002; Lafay-Cousin et al.,
2007),seizuresandhemiparesis(Jiangetal.,2002;Parketal.,2002;
Belenetal.,2007;Hukinetal.,2007),panhypopituitarimus(Hader
et al., 2000; Hukin et al., 2007), blindness (Mottolese et al., 2001;
Belen et al., 2007), and death (Savas et al., 2000). A prospective
randomizedstudyevaluatingintracysticbleomycin(n =5),intra-
cysticradiotherapywithphosphorus32 (n =5),andacombination
of both substances (n =9) revealed severe complications for the
combined therapy resulting in thalamic infarction and death in
two patients (Jiang et al.,2002).
Jakacki et al. (2000) used subcutanous IFN for the treatment of
cystic craniopharyngioma based on the fact that craniopharyn-
gioma and squamous cell skin carcinoma originate from the
same cells and evidence of clinical activity of IFN in squamous
cell skin carcinoma in early trials. In their study 15 cranio-
pharyngioma patients (4.2–19.8years old) underwent daily sub-
cutanous IFN-α 2a (8,000,000U/m2) injections. Three patients
could not be evaluated for response. Of the remaining 12 patients,
3 patients had a radiologically conﬁrmed response to IFN. All
patients experienced fever during the ﬁrst few days of treat-
ment, usually accompanied by chills and myalgias. Seven patients
required temporary discontinuation of the drug and/or dose
reductions.
Intracystic instillation of interferon was ﬁrst used by Cavalheiro
and colleagues who published the ﬁrst and largest experiences
on children with cystic craniopharyngiomas (Cavalheiro et al.,
2005, 2010; Ierardi et al., 2007). Their most recent publication
(Cavalheiro et al., 2010) included 60 children with a mean age
of 11years (20months–18years) who were treated at three dif-
ferent institutions (Sao Paulo/Brazil, Santiago/Chile, Rome/Italy)
from 2000 to 2009. Twenty-nine of the 60 patients received
intracystic IFN after initial surgery (n =18) or bleomycin treat-
ment (n =3) had failed and 31 were treated with IFN as a ﬁrst
line treatment. In 37 patients cyst volume was measured before
and after therapy. The mean cyst volume of 27.7ml (3.3–134.5)
before treatment decreased to a mean volume of 9.6ml (0.14–
70.7) after therapy. While in 47 children (78%) more than 50%
cyst shrinkage was achieved at completion of therapy, 13 chil-
dren progressed and required surgical intervention. Only one-
third of the patients experienced some side effects consisting of
either headaches (n =6), palpebral edema (5), fever (5), chronic
fatigue (1), or arthritis (1) not necessitating discontinuation of
treatment. One patient required optic decompression due to
lack of visual improvement despite cyst shrinkage and eight
patients developed new endocrinological dysfunctions. There was
no mortality.
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FIGURE 1 | SickKids standard of care protocol for intracystic interferon administration.
Based on Cavalheiros experience and initial publication a stan-
dard of care protocol was developed for intracystic IFN admin-
istration (Figure 1) in Toronto. The former intracystic treat-
ment with bleomycin injection was discontinued due to our
experience of bleomycin associated neurotoxicity (Lafay-Cousin
et al., 2007). Roferon-A® (IFN-α 2a), the product used by Cav-
alheiro et al. (2005, 2010) is not available in Canada. Intron-A®
(IFN-α 2b) is available in Canada and although not speciﬁcally
studied in the treatment of craniopharyngiomas, the ready to
use formulation has been given intraventriculary via Ommaya
reservoir for subacute sclerosing panencephalitis (SSPE; Gas-
con, 2003). In this randomized clinical trial including 121 SSPE
patients with a median age 8.5 (3–22)years, IFN-α 2b was ini-
tiated with a 5-day escalating regime from 100,000U/m2 on
day 1 to 1,000,000U/m2 on day 5 followed by treatment of
1,000,000U/m2 twice a week for 6months. Fifty-nine patients
were randomized to the IFN group. The main adverse effect
reportedwashyperpyrexia(n =7)anexpectedsideeffectandwell
www.frontiersin.org March 2012 | Volume 3 | Article 39 | 5Bartels et al. Intracystic therapies for craniopharyngiomas
managed with regular antipyretics. From a clinical perspective,
IFN-α 2a and IFN-α 2b are considered interchangeable for their
licensed indications, at equivalent doses. An “ideal” formulation
of IFNhasnotbeendevelopedforadministrationviaanOmmaya
reservoir.
Since adoption of intracystic IFN at our institution six chil-
drenbetween4and18yearsof age(mean10.8years)weretreated.
Response was measurable in ﬁve children with one complete
response (>90% cyst shrinkage; Figure 2), three partial response
(>50% shrinkage), and one stable disease. Sustained response
was achieved after two to four treatment cycles with a median
follow-up of 17 (1–30)months. All patients suffered manageable
episodes of headaches, one associated with nausea and vomiting
in the initial treatment period. None of the children suffered new
endocrinological dysfunction, evidence of hypothalamic damage
and none of them is obese.
Interferon belongs to a family of proteins with antiprolif-
erative and immunomodulatory functions and its efﬁcacy has
been explained via FasL mediated activation of the apoptotic
pathway (Ierardi et al., 2007). As such Pettorini et al. (2010)
investigated protein content of the cystic ﬂuid in six pediatric
craniopharyngioma patients (mean age 4.5years) and reported
change in ﬂuid content. Those three children who were treated
withintracysticIFNresultinginnearcompleteresponseafteraone
4-week lasting course had signiﬁcant decrease in their total alpha-
defensins (1–3) determined as relevant components of cyst ﬂuids
while the untreated control (n =3) showed increased nanomoles
of alpha-defensins.
CONCLUSION
Intracystic treatment options for cystic craniopharyngioma pro-
vide data suggestive of durable cyst shrinkage and beneﬁt beyond
a pure volume reduction due to repeated ﬂuid aspirations.
The effect however is limited to the cystic craniopharyngioma
portion without an effect on the solid component. There are
multiple challenges relating to technical practicalities: Multi-
cystic occurrence may limit treatment to one cyst only and
therefore this approach does not provide the clinical bene-
ﬁt as wished. The thickness of the cyst wall may not allow
successful penetration of the scope/catheter into the cyst and
different catheter designs make the correct intracystic position-
ing of the catheter and its holes difﬁcult. Intraoperative ultra-
sound and computer tomography (CT) have aided to conﬁrm
correct catheter position; however volume changes during sub-
sequent treatment may inﬂuence the intracystic catheter tip
location.
Most institutions will perform a permeability study prior to
the start of intracystic treatment. The timing of the permeabil-
ity study/dye test depends on the speciﬁc institution and ranges
from 5days postoperatively to several weeks later (Caceres, 2005;
Cavalheiro et al., 2010). A permeability study refers to a CT done
after contrast is injected into the craniopharyngioma cyst to con-
ﬁrm that contrast will remain within the cyst and not leak outside
(Figure 3). Leakage documented on an early performed perme-
ability study has often resolved without further intervention on a
follow-up test after some weeks (Hader et al., 2000). Outﬂow of
substances may occur during treatment either as a result of cyst
shrinkage exposing catheter holes outside of the cyst or as a result
FIGURE3|P e r meability study.
FIGURE 2 | Child with complete maintained response after 2 courses with intracystic interferon.
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of increased permeability of the cyst wall (Lafay-Cousin et al.,
2007).
Hence,despite all diligence,leakage of an intracystic substance
remains a potential risk. Therefore a non-neurotoxic intracystic
medication such as IFN presents a safer treatment option than
radioisotopes or bleomycin and achieved impressive 78% com-
pleteandpartialresponseratesafteraonetoninetreatmentcycles
(average 5; Cavalheiro et al., 2010).
Is cyst shrinkage the appropriate response measurement? A
reduced cyst size will reduce increased pressure to the neighbor-
hoodstructuresandshouldtranslateintoclinicalbeneﬁtregarding
visual, neurocognitive, endocrine, and metabolic function. How-
ever Cavalheiro et al. (2010) describe visual or endocrinological
worsening in one and eight children respectively despite response
to intracystic treatment.
Literature reviews concerning intracystic craniopharyngioma
treatmentstrategiespublishedovertherecentyears(Caceres,2005;
Hargrave, 2006; Linnert and Gehl, 2009; Steinbok and Hukin,
2010) capture the challenge of combining retrospective data
from different institutions that refer to different doses, schedules,
response deﬁnitions,and meaning of success. Cystic response and
ﬁnal outcome may not necessarily correlate. Prognostic marker
n e e dy e tt ob ei d e n t i ﬁ e d( Ierardi et al., 2007, 2009; Pettorini et al.,
2010). Furthermore the role and value of intracystic treatment in
postponingmoreaggressivesurgeryorradiationtherapywillneed
to be deﬁned.
Comparisons and reliable conclusions will remain difﬁcult
unless we as a medical community are agreeable on system-
atic evaluations and deﬁnitions. While randomized clinical trials
are the gold standard for evaluation of best treatment strategies,
they are certainly difﬁcult in the context of rare tumors. Even so
thoughts should be given to potential national and international
cooperation for standardized intracystic treatment strategies. It’s
been 7years that a European consensus was achieved regard-
ing prospective data collection and deﬁnition of parameter for
craniopharyngioma at a meeting of the International Society for
PediatricOncology(SIOP;Mülleretal.,2006).Itistimetoexpand
consensus on prospective data collection on craniopharyngioma
patients to an international level. In doing so we will increase the
size of comparable study cohorts, be able to evaluate meaningful
differences and contribute to improved tailored patient care and
wellbeing.
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